Abstract: Background: These studies compared the diversion and injection of buprenorphine-naloxone (BNX), buprenorphine (BPN) and methadone (MET) in Australia.Methods: Surveys were conducted with regular injecting drug users (IDUs) (2004–2009, N=881–943), opioid substitution treatment (OST) clients (2008, N=440) and authorised OST prescribers (2007, N=291). Key outcome measures include the unsanctioned removal of supervised doses, diversion, injection, motivations, drug liking and street price. Levels of injection among IDUs were adjusted for background availability of medications. Doses not taken as directed by OST clients were adjusted by total number of daily doses dispensed.Results: Among regular IDUs, levels of injection were lower for BNX relative to BPN, but comparable to those …
Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing
Previous post: A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats
Next post: Drug Addiction : How To Get Oxycontin Long-Term Treatment